ALK-Abelló A/S, Allergy Therapeutics, Allergan Plc., Sanofi, and GlaxoSmithKline plc. – Notable Market Participants in Allergy Treatment Industry
The allergy treatment market is highly competitive in nature with considerable number of players, having a high level of consolidation overall revenue share. Most of the companies operating in the allergy treatment market are present globally and have wide distribution and sales network through partnerships or authorized dealers.
The most notable market participants are Johnson and Johnson Services, Inc.; Sanofi; AbbVie Inc. (Allergan plc); Pfizer Inc.; LETIPharma; ALK-Abelló A/S; Allergy Therapeutics; Stallergenes Greer; GlaxoSmithKline plc, and Dermapharm Holding occupying a considerable share of the market owing to their offerings to the market.
Market leaders are involved in extensive research for the development of new allergy treatment with better efficiency and treatment outcomes. For instance, in September 2020, Biotechnology company Allergy Therapeutics announced investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field. It has entered into an exclusive licence agreement with Saiba and DeepVax to use their patented VLP technology platform, to develop and commercialise vaccines targeting solid cancer tumours, atopic dermatitis, asthma, and psoriasis.
Many well-known as well as small local companies are present in the market to provide diversified products to its customers. The larger firms are adopting the strategy of acquiring small firms to enhance its product portfolio and expand its footprint in different geographies. Additionally various companies are also undergoing other strategic alliances such as collaborations and others to garner their significance and remain competitive in the market. Few on the important key developments from the industry are mentioned below:
|
Year |
News |
Region |
|
2020 |
GSK Consumer Healthcare launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerin. The daily usage of the nasal spray washes out the allergens, pollutants, and debris that are trapped in the nasal passage, helping in the removal of allergy symptoms and thus maintaining nasal hygiene. |
Europe |
|
2019 |
Speciality allergy-focussed pharmaceutical company Allergy Therapeutics announced that an ex-vivo biomarker study of blood samples from peanut allergy patients had started at Imperial College London. The study aimed to evaluate its novel virus-like particle (VLP) based peanut allergy vaccine candidate, to confirm its hypoallergenic potential and its potent immune response. |
Europe |
|
2019 |
ALK has announced a partnership with China’s Rellergen Biotech Inc., which grants ALK exclusive promotional rights to market Rellergen’s Bio-IC microfluidic allergen diagnosis technology to more than 190 hospitals across China. |
Asia-Pacific |
